Prediction of improvement in work disability
| Independent variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Diagnosis | ||||
| RA | reference | reference | ||
| AS | 1.477 (1.150; 1.898) | 0.002 | 1.466 (1.044; 2.058) | 0.027 |
| PSA | 1.206 (0.840; 1.731) | 0.310 | 1.226 (0.838; 1.792) | 0.293 |
| Female | 0.821 (0.651; 1.034) | 0.093 | 0.988 (0.754; 1.295) | 0.932 |
| Age at start of anti-TNF therapy | 0.983 (0.971; 0.994) | 0.004 | 0.987 (0.974; 1.001) | 0.067 |
| Disease duration | 0.992 (0.975; 1.009) | 0.341 | 0.998 (0.980; 1.016) | 0.840 |
| HAQ | 1.024 (0.839; 1.251) | 0.815 | 1.181 (0.949; 1.470) | 0.135 |
| Calendar year of starting anti-TNF | ||||
| before 2008 | reference | reference | ||
| 2009–2012 | 0.843 (0.639; 1.113) | 0.228 | 0.799 (0.601; 1.062) | 0.122 |
| 2013–2015 | 1.075 (0.804; 1.438) | 0.624 | 1.001 (0.741; 1.352) | 0.995 |